NexImmune, Inc. (NEXI)

$0.635

+0.06 (+9.71%)
Rating:
Recommendation:
-
Symbol NEXI
Price $0.635
Beta 0.000
Volume Avg. 1.72M
Market Cap 14.697M
Shares () -
52 Week Range 0.51-15.34
1y Target Est -
DCF Unlevered NEXI DCF ->
DCF Levered NEXI LDCF ->
ROE -59.30% Strong Sell
ROA -69.34% Strong Sell
Operating Margin -
Debt / Equity 17.57% Neutral
P/E -
P/B 0.26 Neutral
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest NEXI news


Mr. Scott P. Carmer
Healthcare
Biotechnology
NASDAQ Global Market

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.